155 related articles for article (PubMed ID: 14679018)
21. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.
Perner S; Hofer MD; Kim R; Shah RB; Li H; Möller P; Hautmann RE; Gschwend JE; Kuefer R; Rubin MA
Hum Pathol; 2007 May; 38(5):696-701. PubMed ID: 17320151
[TBL] [Abstract][Full Text] [Related]
22. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
Eggener SE; Roehl KA; Smith ND; Antenor JA; Han M; Catalona WJ
J Urol; 2005 Apr; 173(4):1150-5. PubMed ID: 15758725
[TBL] [Abstract][Full Text] [Related]
23. Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy.
Wang Q; Diao X; Sun J; Chen Z
Urol Oncol; 2013 Apr; 31(3):312-7. PubMed ID: 21367627
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer.
Sillanpää S; Anttila M; Voutilainen K; Ropponen K; Turpeenniemi-Hujanen T; Puistola U; Tammi R; Tammi M; Sironen R; Saarikoski S; Kosma VM
Gynecol Oncol; 2007 Feb; 104(2):296-303. PubMed ID: 17034838
[TBL] [Abstract][Full Text] [Related]
25. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer.
Prtilo A; Leach FS; Markwalder R; Kappeler A; Burkhard FC; Cecchini MG; Studer UE; Thalmann GN
J Urol; 2005 Nov; 174(5):1814-8; discussion 1818. PubMed ID: 16217293
[TBL] [Abstract][Full Text] [Related]
26. Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: prognostic implications and clinical significance for invasion and metastasis.
Miyata Y; Iwata T; Ohba K; Kanda S; Nishikido M; Kanetake H
Clin Cancer Res; 2006 Dec; 12(23):6998-7003. PubMed ID: 17145820
[TBL] [Abstract][Full Text] [Related]
27. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
Swindle P; Eastham JA; Ohori M; Kattan MW; Wheeler T; Maru N; Slawin K; Scardino PT
J Urol; 2005 Sep; 174(3):903-7. PubMed ID: 16093984
[TBL] [Abstract][Full Text] [Related]
28. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of matrix metalloproteinase-2 in cancer of uterine cervix: a semiquantitative study of immunoreactivities using tissue array.
Wang PH; Ko JL; Tsai HT; Yang SF; Han CP; Lin LY; Chen GD
Gynecol Oncol; 2008 Mar; 108(3):533-42. PubMed ID: 18177928
[TBL] [Abstract][Full Text] [Related]
30. The multifunctional role of the immunohistochemical expression of MMP-7 in invasive breast cancer.
Mylona E; Kapranou A; Mavrommatis J; Markaki S; Keramopoulos A; Nakopoulou L
APMIS; 2005 Apr; 113(4):246-55. PubMed ID: 15865605
[TBL] [Abstract][Full Text] [Related]
31. [Prognostic value of stromal immunolabelling by MMP-2, MT1-MMP and TIMP-2 in clinically localized prostate cancer].
Semaan M; Jovenin N; Birembaut P; Menard J; Staerman F
Prog Urol; 2005 Apr; 15(2):250-4. PubMed ID: 15999602
[TBL] [Abstract][Full Text] [Related]
32. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
[TBL] [Abstract][Full Text] [Related]
33. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
[TBL] [Abstract][Full Text] [Related]
34. Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy.
Yanagisawa N; Li R; Rowley D; Liu H; Kadmon D; Miles BJ; Wheeler TM; Ayala GE
Hum Pathol; 2007 Nov; 38(11):1611-20. PubMed ID: 17868773
[TBL] [Abstract][Full Text] [Related]
35. Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression.
Azoulay S; Terry S; Chimingqi M; Sirab N; Faucon H; Gil Diez de Medina S; Moutereau S; Maillé P; Soyeux P; Abbou C; Salomon L; Vacherot F; de La Taille A; Loric S; Allory Y
J Pathol; 2008 Dec; 216(4):460-70. PubMed ID: 18825689
[TBL] [Abstract][Full Text] [Related]
36. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
Bastian PJ; Palapattu GS; Lin X; Yegnasubramanian S; Mangold LA; Trock B; Eisenberger MA; Partin AW; Nelson WG
Clin Cancer Res; 2005 Jun; 11(11):4037-43. PubMed ID: 15930338
[TBL] [Abstract][Full Text] [Related]
37. Decreased stromal expression and increased epithelial expression of WFDC1/ps20 in prostate cancer is associated with reduced recurrence-free survival.
McAlhany SJ; Ayala GE; Frolov A; Ressler SJ; Wheeler TM; Watson JE; Collins C; Rowley DR
Prostate; 2004 Oct; 61(2):182-91. PubMed ID: 15305341
[TBL] [Abstract][Full Text] [Related]
38. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
39. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
Arai T; Fujita K; Fujime M; Irimura T
Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
[TBL] [Abstract][Full Text] [Related]
40. Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome.
Ricciardelli C; Sakko AJ; Stahl J; Tilley WD; Marshall VR; Horsfall DJ
Prostate; 2009 May; 69(7):761-9. PubMed ID: 19189303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]